Novartis AG

Novartis AG

World Rank (Jul-30-2023)
45
Market Cap (Jul-30-2023)
220.82 Billion USD
World Rank (Dec-25-2022)
47
Market Cap (Dec-25-2022)
195.46 Billion USD
World Rank (Jan-07-2022)
61
Market Cap (Jan-07-2022)
201.26 Billion USD
World Rank (Jan-01-2021)
39
Market Cap (Jan-01-2021)
217.77 Billion USD
Company Rank in Country in 2022
Rank in Switzerland in 2022 is 3
World Region
Europe
World Subregion
Western Europe
CEO
Vasant Narasimhan
Chairman
Joerg Reinhardt
Founders
Alexander Clavel
Johann Rudolf Geigy-Merian
Employee Count
101,703
Employee Count as of Date
As on 2022
Headquarters Country
Switzerland
Headquarters City/State
Basel
Annual Revenue in USD
51,830 Million USD
Annual Operating Income in USD
9,190 Million USD
Annual Net Income in USD
6,950 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Total Assets in USD
117,450 Million USD
Total Liabilities in USD
58,030 Million USD
Total Equity in USD
59,423 Million USD
Balance Sheet for Period Ending
Dec-2022 ending year
Business Sector LC
Healthcare
Pharmaceutical
Biotechnology
HealthCare Products
Healthcare Service
Company Website
Novartis - Healthcare and Pharmaceutical Companies in World
Wikipedia
Wikipedia
Yahoo
Yahoo @ NYSE
Facebook
Facebook
Company Profile

Novartis is Switzerland based Multi-National Healthcare and Pharmaceutical company. Novartis Company focus on patented medicines, generic medicines and eye care – segments where they have the innovation power and global scale necessary to compete effectively. At the same time, Novartis is expanding their presence in the emerging markets of Asia, Africa and Latin America, where there is fast-growing demand for access to high- quality medicines and healthcare.

Facts About Company

Novartis annual revenue was 51.83 billion USD for year ending Dec-2022 and annual operating profit was 9.19 billion USD and annual net income was 6.95 billion USD for the same period.

Novartis had over 101,703 employees worldwide as on 2022.

Split of Novartis annual revenue 50,545 billion USD for year ending Dec-2022, Innovative Medicines business segment earned 41,296 million USD revenue and Sandoz business segment earned 9,249 million USD revenue.

Within the Innovative Medicines business segment:
Cardiovascular division earned 4,756 million USD revenue.
Immunology division earned 7,287 million USD revenue.
Neuroscience division earned 5,051 million USD revenue.
Solid Tumors division earned 4,723 million USD revenue.
Hematology division earned 6,452 million USD revenue.
Other Promoted Brands division earned 3,127 million USD revenue.
Established Brands division earned 9,900 million USD revenue.

Annual Results Summary LC

Novartis AG - Yearly Revenues and Profits - in Billion USD:

Year - EndingRevenueOperating IncomeNet Profit
Dec-202251.839.196.95
Dec-202152.8711.6824.02
Dec-202049.8910.158.07
Dec-201948.679.0811.73
Dec-201853.168.1712.61
Dec-201750.138.63 7.70
Dec-201649.43  6.71
Balance Sheet Summary LC

Novartis AG - Balance Sheet Summary - in Million USD:

Year Ending:Total AssetsTotal LiabilitiesTotal Equity
Dec-2022117,45358,03059,423
Dec-2021131,79564,14067,655
Dec-2020132,05975,46156,598
Dec-2019118,37062,89655,474
Dec-2018145,56366,94978,614
Dec-2017133,07958,91174,168
Quarterly Results Summary LC

Novartis AG - Quarter wise Revenues and Profits - in Million USD:

Quarter - EndingRevenueNet Profit
Sep-202312,0921,761
Jun-202313,9362,316
Mar-202313,2082,293
Dec-202213,0871,466
Sep-202212,8421,573
Jun-202213,0851,694
Mar-202212,8142,222
Dec-202113,52216,308
Sep-202113,3672,758
Jun-202113,2942,896
Mar-202112,6942,059
Dec-202013,0302,094
Sep-202012,2591,932
Jun-202011,3471,867
Mar-202012,0782,176
Dec-201912,7161,125
Sep-201912,1722,041
Jun-201912,0246,799
Mar-201911,4551,766
Founded Year
1996
Stock Category LC
S&P EUROPE 350
Stock Exchange LC
NYSE
Switzerland